New Zealand - engelsk - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - clopidogrel bisulfate 97.875mg equivalent to 75 mg clopidogrel;   - film coated tablet - 75 mg - active: clopidogrel bisulfate 97.875mg equivalent to 75 mg clopidogrel   excipient: hydrogenated vegetable oil hyprolose mannitol microcrystalline cellulose opacode black s-1-17823 opadry pink purified water - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - clopidogrel bisulfate 97.875mg equivalent to 75 mg clopidogrel - film coated tablet - 75 mg - active: clopidogrel bisulfate 97.875mg equivalent to 75 mg clopidogrel excipient: castor oil croscarmellose sodium mannitol microcrystalline cellulose opadry pink 03b54202 purified water - prevention of vascular ischaemia associated with atherothrombotic events (mi, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

air flow products limited - clopidogrel bisulfate 97.875mg equivalent to clopidogrel 75 mg - film coated tablet - 75 mg - active: clopidogrel bisulfate 97.875mg equivalent to clopidogrel 75 mg excipient: colloidal silicon dioxide hydrogenated castor oil hyprolose microcelac 100 opadry pink 31k34575 - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome clopidogrel is indicated in combination with aspirin for patients with: - unstable angina or non-st elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death and refractory ischaemia). clopidogrel tablets are indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). - st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, clopidogrel tablets have been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - clopidogrel bisulfate, form ii 97.875mg equivalent to clopidogrel base 75mg;  ;   - film coated tablet - 75 mg - active: clopidogrel bisulfate, form ii 97.875mg equivalent to clopidogrel base 75mg     excipient: carnauba wax hydrogenated castor oil hyprolose macrogol 6000 mannitol microcrystalline cellulose opadry pink 32k14834

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - clopidogrel bisulfate, form ii 97.875mg equivalent to 75 mg free base - film coated tablet - 75 mg - active: clopidogrel bisulfate, form ii 97.875mg equivalent to 75 mg free base excipient: carnauba wax hydrogenated castor oil hyprolose macrogol 6000 mannitol microcrystalline cellulose opadry pink 32k14834 - prevention of vascular ischaemia associated with secondary atherothrombotic events (mi, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome plavix is indicated in combination with aspirin for patients with: · unstable angina or non-st elevation mi. plavix is indicated for early and long-term reduction of atherothrombotic events (myocardial infarction, stroke, vascular death and refractory ischaemia) whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). · st-segment elevation acute myocardial infarction. in this population, plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - clopidogrel bisulfate 97.875mg equivalent to clopidogrel 75 mg - film coated tablet - 75 mg - active: clopidogrel bisulfate 97.875mg equivalent to clopidogrel 75 mg excipient: colloidal silicon dioxide dimeticone hydrogenated castor oil hyprolose instacoat universal pink a05g30176 lactose monohydrate - prevention of vascular ischaemia associated with atherothrombotic events (mi, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease.

USA - engelsk - NLM (National Library of Medicine)

mylan institutional inc. - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - - clopidogrel tablets are indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non-st-segment elevation acs [unstable angina (ua)/non-st-elevation myocardial infarction (nstemi)], including patients who are to be managed medically and those who are to be managed with coronary revascularization. clopidogrel tablets should be administered in conjunction with aspirin . clopidogrel . clopidogrel tablets are indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non-st-segment elevation acs [unstable angina (ua)/non-st-elevation myocardial infarction (nstemi)], including patients who are to be managed medically and those who are to be managed with coronary revascularization. clopidogrel tablets should be administered in conjunction with aspirin . clopidogrel . - clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute st-elevation myocardial infarction (stemi) who are to be managed medically.

USA - engelsk - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopidogrel tablets are indicated to reduce the rate of mi and stroke. clopidogrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. clopidogrel tablets are contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to clopidogrel or any component of the product [see adverse reactions (6.2)] . available data from cases reported in published literature and postmarketing surveillance with clopidogrel use in pregnant women have not identified any drug-associated risks for major birth defects or miscarriage [see data] . there are risks to the pregnant woman and fetus associated with myocardial infarction and stroke [see clinical considerations] . no evidence of fetotoxicity was observed when clopidogrel was administered to pregnant rats and rabbits during organogenesis at doses corresponding to 65 and 78

USA - engelsk - NLM (National Library of Medicine)

cardinal health - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopidogrel tablets are indicated to reduce the rate of mi and stroke. clopidogrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. clopidogrel tablets are contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to clopidogrel or any component of the product [see adverse reactions (6.2)] . reproduction studies performed in rats and rabbits at doses up to 500 and 300 mg/kg/day, respectively (65 and 78 times the recommended daily human dose, respectively, on a mg/m 2 basis), revealed no evidence of impaired fertility or fetotoxicity due to clopidogrel. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of a human response, clopidogrel tablets should be used during pregnancy only if clearly needed. studies in

USA - engelsk - NLM (National Library of Medicine)

remedyrepack inc. - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - - clopidogrel tablets are indicated to reduce the rate of myocardial infarction (mi) and stroke in patients with non–st-segment elevation acs (unstable angina [ua]/non–st-elevation myocardial infarction [nstemi]), including patients who are to be managed medically and those who are to be managed with coronary revascularization. clopidogrel tablets should be administered in conjunction with aspirin. - clopidogrel tablets are indicated to reduce the rate of myocardial infarction and stroke in patients with acute st-elevation myocardial infarction (stemi) who are to be managed medically. clopidogrel tablets should be administered in conjunction with aspirin. in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopidogrel bisulfate tablets are indicated to reduce the rate of mi and stroke. clopidogrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. clopidogrel tab